NASDAQ:BIIBBiogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIIB shares have decreased by 6.0% and is now trading at $276.52. View which stocks have been most impacted by Coronavirus.

32 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 18 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Biogen.

Biogen will be holding an earnings conference call on Wednesday, July 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Biogen Inc (NASDAQ:BIIB) posted its quarterly earnings results on Wednesday, April, 22nd. The biotechnology company reported $9.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.73 by $1.41. The biotechnology company had revenue of $3.53 billion for the quarter, compared to the consensus estimate of $3.41 billion. Biogen had a return on equity of 49.22% and a net margin of 40.76%. The firm's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period last year, the business posted $6.98 EPS. View Biogen's earnings history.

Biogen declared that its board has authorized a share buyback program on Monday, December 23rd 2019, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company's management believes its shares are undervalued.

32 equities research analysts have issued 12-month price targets for Biogen's stock. Their forecasts range from $228.00 to $410.00. On average, they expect Biogen's share price to reach $307.75 in the next year. This suggests a possible upside of 11.3% from the stock's current price. View analysts' price targets for Biogen.

News articles about BIIB stock have been trending very negative on Monday, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Biogen earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Biogen.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Walt Disney (DIS), Celgene (CELG), Micron Technology (MU) and Intel (INTC).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.11%), DNB Asset Management AS (0.09%), MERIAN GLOBAL INVESTORS UK Ltd (0.08%), Wedge Capital Management L L P NC (0.08%), Hexavest Inc. (0.04%) and State of Alaska Department of Revenue (0.04%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin. View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Hexavest Inc., IFM Investors Pty Ltd, Municipal Employees Retirement System of Michigan, Richard P Slaughter Associates Inc, Louisiana State Employees Retirement System, Triangle Securities Wealth Management, and Whittier Trust Co.. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin. View insider buying and selling activity for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, State of Alaska Department of Revenue, Wedge Capital Management L L P NC, Envestnet Asset Management Inc., Cullinan Associates Inc., Patton Fund Management Inc., 6 Meridian, and NuWave Investment Management LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos. View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $276.52.

Biogen has a market capitalization of $45.12 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]